Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | ||||||
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | ||||||
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | ||||||
| 6 | Public support. Subtract line 5 from line 4. | ||||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | ||||||
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | ||||||
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | ||||||
| 11 | Total support. Add lines 7 through 10 | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | 9,775,055 | 13,960,857 | 11,941,446 | 9,978,694 | 8,575,801 | 54,231,853 |
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | 83,008,682 | 88,958,786 | 78,719,498 | 93,297,144 | 136,574,903 | 480,559,013 |
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | 0 | |||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | 0 | |||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | 0 | |||||
| 6 | Total. Add lines 1 through 5 | 92,783,737 | 102,919,643 | 90,660,944 | 103,275,838 | 145,150,704 | 534,790,866 |
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | 12,876,427 | 13,914,277 | 11,641,675 | 9,856,323 | 8,575,801 | 56,864,503 |
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | 0 | |||||
| c | Add lines 7a and 7b.. | 12,876,427 | 13,914,277 | 11,641,675 | 9,856,323 | 8,575,801 | 56,864,503 |
| 8 | Public support. (Subtract line 7c from line 6.) | 477,926,363 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | 92,783,737 | 102,919,643 | 90,660,944 | 103,275,838 | 145,150,704 | 534,790,866 |
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | 5,821,197 | 6,401,944 | 5,651,063 | 5,969,247 | 7,763,043 | 31,606,494 |
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | 0 | |||||
| c | Add lines 10a and 10b. | 5,821,197 | 6,401,944 | 5,651,063 | 5,969,247 | 7,763,043 | 31,606,494 |
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | 3,584,676 | 3,133,751 | 3,414,649 | 2,871,782 | 4,855,029 | 17,859,887 |
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | 306,781 | 277,776 | 248,859 | 255,345 | 1,088,761 | |
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | 102,189,610 | 112,762,119 | 100,004,432 | 112,365,726 | 158,024,121 | 585,346,008 |
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by .035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | ||
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
||
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | ||
| 4 Amounts paid to acquire exempt-use assets | ||
| 5 Qualified set-aside amounts (prior IRS approval required) | ||
| 6 Other distributions (describe in Part VI). See instructions | ||
| 7Total annual distributions. Add lines 1 through 6. | ||
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
||
| 9 Distributable amount for 2018 from Section C, line 6 | ||
| 10 Line 8 amount divided by Line 9 amount | ||
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2018 |
(iii) Distributable Amount for 2018 |
|
|---|---|---|---|---|
|
1
Distributable amount for 2018 from Section C, line 6 |
||||
|
2
Underdistributions, if any, for years prior to 2018 (reasonable cause required-- explain in Part VI). See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2018: | ||||
| a From 2013....... | ||||
| b From 2014....... | ||||
| c From 2015....... | ||||
| d From 2016....... | ||||
| e From 2017....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2018 distributable amount | ||||
|
i
Carryover from 2013 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from 3f. | ||||
| 4Distributions for 2018 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2018 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from 4. | ||||
|
5
Remaining underdistributions for years prior to 2018, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2018. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2019. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2014...... | ||||
| b Excess from 2015..... | ||||
| c Excess from 2016..... | ||||
| d Excess from 2017..... | ||||
| e Excess from 2018..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| FORM 990, PART III, LINE 1 | ASCO IS A PROFESSIONAL ONCOLOGY SOCIETY COMMITTED TO CONQUERING CANCER THROUGH RESEARCH, EDUCATION, AND PROMOTION OF THE HIGHEST QUALITY PATIENT CARE. ASCO'S VISION IS A WORLD WHERE CANCER IS PREVENTED OR CURED, AND EVERY SURVIVOR IS HEALTHY. ASCO PROMOTES AND PROVIDES FOR: - CANCER RESEARCH, - AN IMPROVED ENVIRONMENT FOR ONCOLOGY PRACTICE, - ACCESS TO QUALITY CANCER CARE, - A GLOBAL NETWORK OF ONCOLOGY EXPERTISE, AND - EDUCATED AND INFORMED PATIENTS WITH CANCER. |
| FORM 990, PART III, LINE 4A | QUALITY OF CARE: ASCO PRODUCES EVIDENCE-BASED GUIDELINES, DEVELOPS AND VALIDATES QUALITY MEASURES IN ONCOLOGY, AND CONDUCTS QUALITY MEASUREMENT AND IMPROVEMENT ACTIVITIES PROGRAMS INCLUDE: -CANCERLINQ. THIS BIG-DATA BASED, RAPID LEARNING SYSTEM IN ONCOLOGY HAS BEEN DEVELOPED, BY ASCO'S WHOLLY-OWNED SUBSIDIARY, CANCERLINQ LLL, TO VASTLY IMPROVE THE WAY ONCOLOGISTS PRACTICE, LEARN, AND DETERMINE THE BEST TREATMENT OPTIONS FOR THEIR PATIENTS. -QUALITY ONCOLOGY PRACTICE INITIATIVE (QOPI). A QUALITY ASSESSMENT AND IMPROVEMENT PROGRAM FOR OUTPATIENT MEDICAL ONCOLOGY AND HEMATOLOGY-ONCOLOGY PRACTICES. QOPI PROVIDES A WEB-BASED DATA COLLECTION TOOL THAT ALLOWS PRACTICE STAFF TO 1) REPORT ON VARIOUS CANCER CARE QUALITY MEASURES, 2) RECEIVE ANALYZED DATA ON PRACTICE PERFORMANCE, AND 3) COMPARE PERFORMANCE AGAINST THEIR PEERS FOR DATA-DRIVEN IMPROVEMENT ACTIVITIES. - CLINICAL PRACTICE GUIDELINES AND UPDATES. ASCO HAS PUBLISHED MORE THAN 50 PRACTICE GUIDELINES, ENDORSEMENTS, AND PROVISIONAL CLINICAL OPINIONS (PCO'S) ADDRESSING A WIDE RANGE OF CANCER TREATMENT, DIAGNOSIS, AND MANAGEMENT ISSUES. - QOPI REPORTING REGISTRY. ASCO PROVIDES A QUALIFIED CLINICAL DATA REGISTRY TO HELP MEMBERS SATISFY THE FEDERAL GOVERNMENTS MERIT-BASED INCENTIVE PAYMENT SYSTEM (MIPS) REPORTING REQUIREMENTS. - QUALITY TRAINING PROGRAM. ASCOS QUALITY TRAINING PROGRAM IS DESIGNED TO HELP PRACTICES IMPROVE CLINICAL CARE AND OPERATIONAL PERFORMANCE. IN ADDITION, ASCO OFFERS PRACTICE MANAGEMENT PROGRAMS AND PRODUCTS DESIGNED TO SUPPORT PRACTICE HEALTH TO ENABLE PRACTICES TO DELIVER HIGH QUALITY CARE. THESE RESOURCES INCLUDE: - PRACTICENET. THIS LEARNING NETWORK IS FOCUSED ON HELPING PRACTICES IMPROVE THEIR BUSINESS OPERATIONS - FDA ALERTS. ASCO PARTNERS WITH THE FDA TO PROVIDE ITS MEMBERS TIMELY SAFETY ALERTS AND NOTICES OF NEWLY APPROVED CANCER THERAPIES. |
| FORM 990, PART III, LINE 4B | SCIENTIFIC AND MEDICAL EDUCATION: ASCO PROVIDES SCIENTIFIC AND EDUCATIONAL PROGRAMS AND CONTENT ON A BROAD RANGE OF ONCOLOGY-RELATED TOPICS IN A VARIETY OF FORMATS. WORKING WITH VOLUNTEER ASCO MEMBERS, ASCO PLANS AND PRESENTS LIVE MEETINGS ON THE LATEST RESEARCH AND ADVANCES IN THE FIELD OF CLINICAL ONCOLOGY. THE ONCOLOGY-SPECIFIC INFORMATION PRESENTED AT THESE MEETINGS ENHANCES KNOWLEDGE ABOUT TREATING CANCER AND CARING FOR CANCER PATIENTS. THE ASCO ANNUAL MEETING IS THE WORLD'S PREMIER SCIENTIFIC AND EDUCATIONAL MEETING IN THE ONCOLOGY COMMUNITY. THE THEMATIC MEETINGS, PRESENTED OR CO-SPONSORED BY ASCO, PROVIDE OPPORTUNITIES FOR FOCUSED EDUCATIONAL AND SCIENTIFIC SESSIONS ON SPECIFIC TYPES OF CANCERS. ASCO'S PROGRAMS ARE DESIGNED TO SERVE THE DIVERSE NEEDS OF ONCOLOGY PRACTITIONERS WORLDWIDE TO ASSIST THEM IN DELIVERING HIGH QUALITY CANCER CARE AND CONDUCTING CLINICAL RESEARCH THROUGH THE CONTINUUM OF THEIR CAREERS. PROGRAMS ADDRESS THE MODERN-DAY PRACTICE OF ONCOLOGY FOR ALL LEVELS OF PRACTITIONERS INCLUDING ONCOLOGY FELLOWS, JUNIOR FACULTY MEMBERS, ONCOLOGY PROGRAM DIRECTORS, ETC. ASCO'S EDUCATIONAL PROGRAMS INCLUDE PLANNING, IMPLEMENTATION AND EVALUATION OF CONTINUING MEDICAL EDUCATION (CME) TO SUPPORT THE CONTINUED EDUCATION OF ONCOLOGISTS AND OTHER MEMBERS OF THE CANCER CARE TEAM TO ENABLE THEM TO BETTER MEET THE PREVENTION, DIAGNOSIS AND TREATMENT NEEDS OF THEIR PATIENTS. CURRENTLY, ASCO HOLDS THE STATUS OF ACCREDITATION WITH COMMENDATION FROM THE ACCREDITATION COUNCIL FOR CME FOR ASCO'S CME PROGRAM. ASCO MAKES MUCH OF THE CONTENT FROM ITS MEETINGS AND OTHER EDUCATIONAL AND SCIENTIFIC CONTENT PUBLICLY AVAILABLE THROUGH TWO ASCO WEBSITES: WWW.ASCO.ORG AND WWW.CANCER.NET. ADDITIONALLY, ASCO MAKES SCIENTIFIC AND EDUCATIONAL MATERIALS AVAILABLE THROUGH A VARIETY OF CHANNELS, INCLUDING BOOKS, DVDS, VIRTUAL MEETINGS, PODCASTS AND PUBLIC FORUMS. HIGHLIGHTS OF THE 2018 ACTIVITIES INCLUDE: OVER 40,000 PEOPLE ATTENDED THE 2018 ASCO ANNUAL MEETING, INCLUDING PHYSICIANS, NURSES, CAREGIVERS, PATIENTS, AND PATIENT ADVOCATES. APPROXIMATELY 40% OF THE ATTENDEES AT THE 2018 ASCO ANNUAL MEETING WERE INTERNATIONAL ATTENDEES. THE 2018 ANNUAL MEETING FEATURED OVER 265 EDUCATIONAL AND SCIENTIFIC SESSIONS AND OVER 5,000 ABSTRACTS WERE PRESENTED OR PUBLISHED. NEARLY 5,000 PRESENTATIONS WERE CAPTURED IN AUDIO AND VIDEO TO BE MADE AVAILABLE ELECTRONICALLY. IN ADDITION TO THE ASCO ANNUAL MEETING, ASCO SPONSORS OR CO-SPONSORS MORE THAN 40 EDUCATIONAL AND SCIENTIFIC SYMPOSIA, WORKSHOPS, AND COURSES INSIDE AND OUTSIDE THE UNITED STATES ON A WIDE VARIETY OF CANCER-RELATED TOPICS TO IMPROVE ONCOLOGY CARE WORLDWIDE. THESE MEETINGS INCLUDE: - BEST OF ASCO - PALLIATIVE AND SUPPORTIVE CARE IN ONCOLOGY SYMPOSIUM - QUALITY CARE SYMPOSIUM - GASTROINTESTINAL CANCERS SYMPOSIUM - GENITOURINARY CANCERS SYMPOSIUM - CANCER SURVIVORSHIP SYMPOSIUM - CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM INTERNATIONAL AFFAIRS MEETINGS AND COURSES: - BEST OF ASCO INTERNATIONAL - JOINT SYMPOSIA - ADVANCED CANCER COURSES - MULTIDISCIPLINARY CANCER MANAGEMENT COURSES ASCO PUBLISHES DAILY NEWS PRODUCTS FOR EACH OF ITS MAJOR MEETINGS. THESE PRODUCTS INCLUDE PRINT NEWSPAPERS THAT ARE DISTRIBUTED ONSITE TO ALL ATTENDEES AND PUBLICLY AVAILABLE ONLINE. THE DAILY NEWS PRODUCTS PROVIDE EDITORIAL COVERAGE OF KEY MEETING SESSIONS, COMMENTARIES BY EXPERTS IN VARIOUS SUBSPECIALTIES, INFORMATION ABOUT ASCO PRODUCTS AND RESOURCES, PROFILES OF GRANT AND AWARD WINNERS, AND OTHER TOPICS OF INTEREST TO ASCO MEMBERS AND MEETING ATTENDEES FROM AROUND THE WORLD. |
| FORM 990, PART III, LINE 4C | SCIENTIFIC PUBLICATIONS: ASCO PRODUCES A NUMBER OF PROFESSIONAL PUBLICATIONS FOCUSED ON CLINICAL ONCOLOGY. - ASCO PUBLISHES SEVERAL PEER-REVIEWED SCIENTIFIC JOURNALS - JOURNAL OF CLINICAL ONCOLOGY (JCO) IS A HIGHLY REGARDED, PEER-REVIEWED JOURNAL THAT DISSEMINATES QUALITY ARTICLES ON SIGNIFICANT CLINICAL ONCOLOGY RESEARCH IN PRINT AND ELECTRONIC FORMATS. - JOURNAL OF ONCOLOGY PRACTICE (JOP) INCLUDES ORIGINAL RESEARCH AND PERSPECTIVES ON CLINICAL AND ADMINISTRATIVE MANAGEMENT ADDRESSING THE PRACTICE OF ONCOLOGY, WHICH ARE EDITED BY ONCOLOGISTS. - THE JOURNAL OF GLOBAL ONCOLOGY (JGO) IS AN ONLINE ONLY, OPEN ACCESS JOURNAL FOCUSED ON CANCER CARE, RESEARCH AND CARE DELIVERY ISSUES UNIQUE TO COUNTRIES AND SETTINGS WITH LIMITED HEALTHCARE RESOURCES. - JCO CLINICAL CANCER INFORMATICS IS AN ONLINE-ONLY INTERDISCIPLINARY JOURNAL PUBLISHING CLINICALLY RELEVANT RESEARCH BASED ON BIOMEDICAL INFORMATICS METHODS AND PROCESSES APPLIED TO CANCER-RELATED DATA, INFORMATION AND IMAGES. - JCO PRECISION ONCOLOGY IS A PEER-REVIEWED, ONLINE-ONLY, ARTICLE BASED JOURNAL PUBLISHING ORIGINAL RESEARCH, REPORTS, OPINIONS AND REVIEWS THAT ADVANCE THE SCIENCE AND PRACTICE OF PRECISION ONCOLOGY AND DEFINE GENOMICS-DRIVEN CLINICAL CARE OF PATIENTS WITH CANCER. -ASCO PUBLISHES THE ANNUAL CLINICAL CANCER ADVANCES (CCA) REPORT. THIS PUBLICLY-AVAILABLE REPORT ESTABLISHES THE MOST IMPORTANT CLINICAL ADVANCES IN ONCOLOGY EACH YEAR. THE REPORT SERVES TO DOCUMENT THE PROGRESS BEING MADE AGAINST CANCER THROUGH CLINICAL RESEARCH, PARTICULARLY THROUGH FEDERALLY FUNDED RESEARCH. ASCO IS INVOLVED IN THE PRODUCTION OF THE ASCO POST, A TRADE PUBICATION. WHILE NOT OWNED OR PUBLISHED BY ASCO, THIS TRADE COVERS NEWS AND INFORMATION OF INTEREST TO THE PROFESSIONAL ONCOLOGY COMMUNITY AND ASCO PROVIDES ASCO-SPECIFIC CONTENT FOR INCLUSION. |
| FORM 990, PART III, LINE 4D | CANCER POLICY AND ADVOCACY: ASCOS POLICY AND ADVOCACY WORK FOCUSES ON THE ISSUES OF ACCESS TO AND DELIVERY OF HIGH-QUALITY CANCER CARE FOR CANCER PATIENTS. WORKING WITH VOLUNTEER ASCO MEMBERS, THE SOCIETY ENGAGES WITH THE ADMINISTRATION, CONGRESS, AND STATE LAW MAKERS TO ADDRESSES POLICY ISSUES OF CRITICAL IMPORTANCE TO THE PRACTICE OF ONCOLOGY AND PATIENT CARE. ASCO'S POLICY AND ADVOCACY PROGRAMS COVER A BROAD SPECTRUM OF ISSUES, INCLUDING CLINICAL CANCER RESEARCH, HEALTH INSURANCE, CLINICAL PRACTICE, WORKFORCE, DISPARITIES, COST/ACCESS, CANCER SURVIVORSHIP, AND CANCER PREVENTION AND CONTROL. ASCO PROVIDES EDUCATIONAL WORKSHOPS AND MATERIALS, LEGAL ANALYSIS, DEVELOPMENT OF FORMAL COMMENTS AND TESTIMONY, ADVOCACY, HOTLINES, TOOLS, AND SPECIAL STUDIES ON CRITICAL ISSUES FOR THE CANCER COMMUNITY. ASCO ROUTINLEY COLLABORATES WITH OTHERS IN THE COMMUNITY TO ADVANCE COMMON GOALS RELATED TO ACCESS TO AND DELIVERY OF HIGH-QUALITY CANCER CARE. - STATE/REGIONAL AFFILIATE PROGRAM. THE 48 STATE/REGIONAL AFFILIATES INTERACT WITH ASCO THROUGH THE STATE AFFILIATE COUNCIL, WHERE EACH SOCIETY HAS A VOTING REPRESENTATIVE CHARGED WITH SERVING AS THE BRIDGE BETWEEN THE SOCIETY AND ASCO. AFFILIATES HAVE ACCESS TO A NUMBER OF PROGRAMS INCLUDING STATE SOCIETY MEMBERSHIP RECRUITMENT AND RETENTION ASSISTANCE, LEADERSHIP TRAINING, FEDERAL-LEVEL ADVOCACY SUPPORT, EDUCATION AND RESOURCES ON PRACTICE-RELATED ISSUES, AND A WEBSITE DEVELOPMENT TOOL. ORIGINAL DATA COLLECTION. ASCO CONDUCTS STUDIES AND ANALYSES TO ASSESS THE CURRENT STATE OF ONCOLOGY CARE AND RESEARCH AND DETERMINE THE NEED FOR AND IMPACT OF POLICY CHANGES. EXPENSES $11,277,636. INCLUDING GRANTS OF $0. REVENUE $89,243. MEMBER SERVICES: ASCO WORKS TO SUPPORT AND EDUCATE ITS MORE THAN 44,000 MEMBERS THROUGH ITS DAILY ACTIVITIES, INCLUDING PROCESSING NEW MEMBERSHIP APPLICATIONS AND MEMBER DUES, PHONE AND EMAIL COMMUNICATIONS, RESEARCHING AND FULFILLING MEMBER REQUESTS, MAINTAINING THE INTEGRITY OF MEMBER DATA, AND NEW MEMBER RECRUITMENT AND RETENTION EFFORTS. ASCO CONNECTION IS THE OFFICIAL MEMBER MAGAZINE FOR AND ABOUT MEMBERS OF ASCO AND THE PRIMARY SOURCE OF INFORMATION ABOUT ASCO'S PROGRAMS AND SERVICES. ALONG WITH ITS COMPANION PROFESSIONAL NETWORKING SITE, ASCOCONNECTION.ORG, ASCO CONNECTION PROMOTES OPPORTUNITIES FOR INTERACTION BETWEEN ASCO AND ITS MEMBERS, AND MEMBERS AND THEIR COLLEAGUES TO FACILITATE THE DISSEMINATION OF INFORMATION RELATING TO CLINICAL RESEARCH, BEST PRACTICES STANDARDS, AND TREATMENT OF PATIENTS. ASCOCONNECTION.ORG FEATURES COMMENTARY BY LEADERS IN THE FIELD, DISCUSSION FORUMS, ONLINE EXCLUSIVES AND COMMENT-ENABLED ARTICLES FROM THE MEMBER MAGAZINE, AS WELL AS OPPORTUNITIES TO CREATE GROUPS. EXPENSES $8,988,354. INCLUDING GRANTS OF $690,327. REVENUE $7,373,722. RESEARCH: ASCO IS ACTIVELY ENGAGED IN THE SUPPORT, PROMOTION AND CONDUCT OF CLINICAL CANCER RESEARCH. RESEARCH RELATED ACTIVITIES INCLUDE: - RESEARCH COMMUNITY FORUM (RCF). ASCO PROVIDES A NETWORK (ONLINE AND IN-PERSON) FOR ALL MEMBERS OF THE ONCOLOGY RESEARCH COMMUNITY TO PROMOTE BEST PRACTICES FOR CONDUCTING AND MANAGING CLINICAL RESEARCH. - ORIGINAL RESEARCH. ASCO CONDUCTS RESEARCH TO DEVELOP EVIDENCE THAT INFORMS PATIENT CARE, PUBLIC POLICY, AND EDUCATION. RESEARCH INCLUDES SURVEYS, OBSERVATIONAL STUDIES AND CLINICAL TRIALS. o TAPUR. ASCO IS CONDUCTING A CLINICAL TRIAL TO TEST THE SAFETY AND EFFICACY OF FDA-APPROVED, TARGETED ANTICANCER DRUGS IN OTHER CANCER TYPES FOR PATIENTS WITH THE SAME GENOMIC ALTERATION. -SCIENTIFIC/RESEARCH COLLABORATIONS. ASCO WORKS WITH OTHER STAKEHOLDERS IN THE COMMUNITY, INCLUDING GOVERNMENT AGENCIES, PATIENT ADVOCACY GROUPS, AND OTHER PROFESSIONAL MEDICAL SOCIETIES TO SUPPORT AND PROMOTE RESEARCH THAT INFORMS EVIDENCE-BASED PATIENT CARE. o ASCO-FDA SCIENTIFIC COLLABORATIONS. ASCO JOINTLY HOSTS PUBLIC WORKSHOPS WITH THE FDA TO PROVIDE STAKEHOLDERS AN OPPORTUNITY TO DISCUSS EMERGING ISSUES IN RESEARCH AND FDA REVIEW OF NEW THERAPIES. - DATA/RESEARCH REQUESTS. ASCO REVIEWS 3RD PARTY REQUESTS TO CONDUCT RESEARCH USING THE SOCIETYS PROPRIETARY ASSETS. EXPENSES $8,655,038. INCLUDING GRANTS OF $0. REVENUE $5,936,693. PATIENT INFORMATION & OTHER: ASCO PROVIDES IMPORTANT INFORMATION ABOUT CANCER, CANCER CARE, TREATMENT, RESEARCH, AND PREVENTION FREE OF CHARGE TO THE PUBLIC. ASCOS PATIENT EDUCATION WEBSITE, CANCER.NET (WWW.CANCER.NET) IS PUBLICLY AVAILABLE AND PROVIDES RELIABLE CANCER INFORMATION FROM A TRUSTED SOURCE TO ASCO MEMEBERS, THEIR PATIENTS, CAREGIVERS, FAMILY MEMBERS AND OTHERS. THE SITE PROVIDES ACCURATE, ONCOLOGIST-APPROVED INFORMATION ABOUT CANCER, CANCER CARE, TREATMENT, SURVIVORSHIP, RESEARCH, PREVENTION, AND OTHER IMPORTANT TOPICS. THE SITE FEATURES MEDICAL INFORMATION ON MORE THAN 120 TYPES OF CANCER AND RELATED SYNDROMES. IN ADDITION, INFORMATION ON CLINICAL TRIALS, MANAGING SIDE EFFECTS, CAREGIVING, AND HOW TO COPE WITH THE EMOTIONAL AND SOCIAL EFFECTS OF LIVING WITH CANCER CAN BE FOUND ON THE SITE. ASCO ALSO OFFERS PRINTED MATERIALS FOR PATIENTS INCLUDING: - CANCER.NET'S GUIDES TO CANCER. THESE DETAILED GUIDES COVER SYMPTOMS, RISK FACTORS, DIAGNOSIS, STAGING, TREATMENT, CLINICAL TRIAL RESOURCES, SIDE EFFECTS, AFTER TREATMENT, CURRENT RESEARCH AND QUESTIONS TO ASK THE DOCTOR, - ASCO ANSWERS FACT SHEETS. FACT SHEETS PROVIDE AN INTRODUCTION TO A SPECIFIC TYPE OF CANCER OR CANCER-RELATED TOPIC, INCLUDING AN OVERVIEW, AN ILLUSTRATION OF WHERE IT STARTS, HOW IT IS TREATED, TERMS TO KNOW, AND QUESTIONS TO ASK THE DOCTOR. INFORMATIONAL BOOKLETS. BOOKLETS ARE AVAILABLE ON POPULAR TOPICS OF INTEREST: TOBACCO CESSATION, CANCER SURVIVORSHIP, ADVANCED CANCER CARE PLANNING, MANAGING THE COST OF CANCER CARE, AND CANCER IN OLDER ADULTS. EXPENSES $6,599,547. INCLUDING GRANTS OF $0. REVENUE $210,931. |
| FORM 990, PART VI, SECTION A, LINE 1 | AS OF DECEMBER 31, 2018, THE BOARD OF DIRECTORS OF ASCO INCLUDED 18 MEMBERS WITH THE RIGHT TO VOTE ON ALL MATTERS THAT COME BEFORE THE BOARD OF DIRECTORS. THE BOARD OF DIRECTORS ALSO INCLUDES TWO EX-OFFICIO DIRECTORS WITHOUT THE RIGHT TO VOTE, WHO ARE THE CHIEF EXECUTIVE OFFICER OF ASCO (CEO) AND THE CHAIR OF THE BOARD OF DIRECTORS OF CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (A NON-PROFIT, 501(C)(3) TAX-EXEMPT RELATED ORGANIZATION OF ASCO). DURING THE REPORTING YEAR, THE BOARD OF DIRECTORS DELEGATED AUTHORITY TO ACT ON ITS BEHALF TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. THE VOTING MEMBERS OF THE EXECUTIVE COMMITTEE WERE: THE PRESIDENT, PRESIDENT-ELECT, THE CHAIR, THE PAST PRESIDENT, AND THOSE DIRECTORS SERVING THE FINAL YEAR OF THEIR PRESENT TERMS. THE CEO IS A NON-VOTING MEMBER OF THE EXECUTIVE COMMITTEE. ALL EXECUTIVE COMMITTEE MEMBERS ARE MEMBERS OF ASCO'S BOARD OF DIRECTORS. THE SCOPE OF THE EXECUTIVE COMMITTEE'S AUTHORITY IS ESTABLISHED BY ASCO'S BYLAWS, WHICH PROVIDE THAT, EXCEPT TO THE EXTENT SPECIFICALLY PROHIBITED BY RESOLUTION OF THE BOARD OF DIRECTORS OR OTHERWISE PROHIBITED BY LAW, THE EXECUTIVE COMMITTEE OF THE BOARD IS EMPOWERED TO MAKE AND IMPLEMENT MAJOR DECISIONS BETWEEN BOARD MEETINGS AND IT MAY ACT ON ITEMS REQUIRING ACTION PRIOR TO THE NEXT ANNOUNCED BOARD OF DIRECTORS. ALL ACTIONS OF THE EXECUTIVE COMMITTEE ARE REPORTED TO THE BOARD OF DIRECTORS AT THE NEXT MEETING OF THE BOARD OF DIRECTORS IMMEDIATELY FOLLOWING THE ACTION TAKEN BY THE EXECUTIVE COMMITTEE, CONSISTENT WITH ASCO'S BYLAWS. |
| FORM 990, PART VI, SECTION A, LINE 6 | ASCO MEMBERS ARE ELECTED BY THE BOARD OF DIRECTORS, CONSISTENT WITH ASCO'S BYLAWS. NO MEMBER IS ENTITLED TO RECEIVE A SHARE OF ASCO'S PROFITS OR EXCESS DUES OR A SHARE OF ASCO'S NET ASSETS UPON DISSOLUTION. THE CATEGORIES OF MEMBERSHIP WITH VOTING RIGHTS AND SPECIFIED RIGHTS ARE AS FOLLOWS: 1. FULL MEMBERS. a. 1.A. FULL MEMBERS ARE (A) EXPERIENCED LICENSED PHYSICIANS OF ANY NATION WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO CANCER PATIENT CARE AND/OR RESEARCH OR EDUCATION IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER (IN EXCEPTIONAL CASES, OTHER PHYSICIANS WHO HAVE MADE SIGNIFICANT CONTRIBUTIONS TO THE FIELD ARE ELIGIBLE FOR FULL MEMBER STATUS), AND (B) OTHER HEALTH PROFESSIONALS AT THE DOCTORAL LEVEL (E.G.,EPIDEMIOLOGISTS, BIOSTATISTICIANS, PUBLIC HEALTH SPECIALISTS, NURSES, OTHER SCIENTISTS, ETC.) OR INDIVIDUALS WITH EQUIVALENT ACADEMIC RANKS WHO DEVOTE A MAJORITY OF THEIR PROFESSIONAL ACTIVITY TO CANCER PATIENT CARE AND/OR RESEARCH OR EDUCATION IN THE BIOLOGY, DIAGNOSIS, PREVENTION OR TREATMENT OF HUMAN CANCER. b.1.B. RIGHTS OF FULL MEMBERS INCLUDE THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. 2. EMERITUS MEMBERS. a.2.A. EMERITUS MEMBERS ARE FULL, ALLIED PHYSICIAN/DOCTORAL SCIENTIST, INTERNATIONAL CORRESPONDING AND AFFILIATED HEALTH PROFESSIONAL MEMBERS WHO HAVE REQUESTED EMERITUS STATUS AT AGE 70, UPON RETIREMENT OR EARLIER IF PERMANENTLY DISABLED. b.2.B. EMERITUS MEMBERS WHO AT THE TIME OF THE REQUEST WERE FULL MEMBERS RETAIN THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. 3. HONORARY MEMBERS. a.3.A. HONORARY MEMBERS ARE INDIVIDUALS WHO HAVE MADE AN OUTSTANDING CONTRIBUTION TO CLINICAL ONCOLOGY WHO ARE DESIGNATED AS AN HONORARY MEMBER BY THE BOARD OF DIRECTORS. b.3.B. MEMBERS HAVE THE RIGHT TO ATTEND MEETINGS, VOTE ON THE ELECTION OF ELECTED DIRECTORS, ELECTED OFFICERS, AND CERTAIN COMMITTEE MEMBERS, AND APPROVE SIGNIFICANT DECISIONS OF THE GOVERNING BODY SUCH AS AMENDMENT TO THE GOVERNING DOCUMENTS AND DISSOLUTION. |
| FORM 990, PART VI, SECTION A, LINE 7A | VOTING MEMBERS OF ASCO ELECT ALL 18 VOTING MEMBERS OF THE ASCO BOARD OF DIRECTORS. THE CATEGORIES OF MEMBERS WHO ARE ELIGIBLE TO VOTE FOR THE ELECTION OF MEMBERS OF THE GOVERNING BODY ARE: FULL MEMBERS, EMERITUS MEMBERS WHO WERE FULL MEMBERS AT THE TIME OF REQUEST FOR EMERITUS MEMBER STATUS, AND HONORARY MEMBERS. |
| FORM 990, PART VI, SECTION A, LINE 7B | ASCO'S CERTIFICATE OF INCORPORATION MAY ONLY BE AMENDED UPON THE VOTE OF THE MEMBERS ENTITLED TO VOTE, AND THE BYLAWS MAY ONLY BE AMENDED AND DISSOLUTION OF THE CORPORATION MAY ONLY BE APPROVED WITH THE APPROVAL OF BOTH THE BOARD OF DIRECTORS AND VOTING MEMBERS OF ASCO. THE CATEGORIES OF MEMBERS WHO ARE ELIGIBLE TO VOTE ARE: FULL MEMBERS, EMERITUS MEMBERS WHO WERE FULL MEMBERS AT THE TIME OF REQUEST FOR EMERITUS MEMBER STATUS, AND HONORARY MEMBERS. |
| FORM 990, PART VI, SECTION A, LINE 9 | UNFORTUNATELY, ASCO BOARD MEMBER DR. ARTI HURRIA PASSED AWAY IN 2018, AND THEREFORE CANNOT BE REACHED AT THE ORGANIZATION'S MAILING ADDRESS. |
| FORM 990, PART VI, SECTION B, LINE 11 | AN ELECTRONIC COPY OF THE ASCO FORM 990 WAS SENT, THROUGH A SECURE SITE, TO EACH MEMBER OF THE BOARD OF DIRECTORS AND WAS DISCUSSED AT A MEETING OF THE BOARD BEFORE IT WAS FILED. THE ASCO FORM 990 WAS REVIEWED BY THE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, THE CHIEF EXECUTIVE OFFICER, AND THE SENIOR VICE PRESIDENT AND CHIEF LEGAL OFFICER PRIOR TO FILING. |
| FORM 990, PART VI, SECTION B, LINE 12C | ASCO MAINTAINS A NUMBER OF WRITTEN CONFLICT OF INTEREST POLICIES AND STANDARDS REGARDING THE DISCLOSURE AND MANAGEMENT OF CONFLICTS OF INTEREST. THESE POLICIES AND STANDARDS COVER ALL ASCO MEMBERS AND EMPLOYEES, DIRECTORS, OFFICERS, COMMITTEE MEMBERS, AND ANY PERSON IN A RELATIONSHIP WITH THESE INDIVIDUALS INVOLVING THE SHARING OF INCOME OR ASSETS (E.G. SPOUSE, DEPENDENT CHILDREN). COVERED INDIVIDUALS ARE ASKED TO DISCLOSE FINANCIAL INTERESTS IN OR OTHER RELATIONSHIPS WITH ENTITIES THAT HAVE RELEVANT COMMERCIAL INTERESTS, INCLUDING EMPLOYMENT OR LEADERSHIP POSITIONS, CONSULTANT OR ADVISORY ROLES, STOCK OWNERSHIP, HONORARIA, RESEARCH FUNDING, AND SERVICE AS AN EXPERT WITNESS. OFFICERS, DIRECTORS AND KEY EMPLOYEES ARE ALSO REQUIRED TO DISCLOSE SERVICE AS AN OFFICER, DIRECTOR, OR TRUSTEE OF ANY OTHER PROFESSIONAL OR ADVOCACY ORGANIZATION RELATING TO SCIENCE OR HEALTH CARE. COMPLETION OF A DISCLOSURE FORM IS REQUIRED AT THE INITIATION OF SERVICE AND UPDATED ANNUALLY THEREAFTER OR WHEN ANY MATERIAL CHANGES OCCUR. ASCO'S CONFLICT OF INTEREST POLICIES ARE INTENDED TO HELP GUIDE THE MANAGEMENT OF ACTUAL, POTENTIAL, AND PERCEIVED CONFLICTS OF INTEREST THROUGH DISCLOSURE OF FINANCIAL INTERESTS OR OTHER RELATIONSHIPS. WHERE THE NATURE AND EXTENT OF A FINANCIAL RELATIONSHIP SUGGEST DISCLOSURE IS NOT ADEQUATE TO MANAGE A REAL OR POTENTIAL CONFLICT, COVERED INDIVIDUALS ARE REQUIRED TO RECUSE THEMSELVES FROM DECISION MAKING. RECUSAL MAY BE SELF-SELECTED, OR MAY BE REQUESTED BY THE COMMITTEE CHAIR, OFFICER, OR EXECUTIVE-LEVEL STAFF MEMBERS. IN ADDITION, IF ASCO WERE TO CONTEMPLATE ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF ANY INTERESTED PERSON (I.E. AN ASCO DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF AN ASCO COMMITTEE WITH BOARD DELEGATED POWERS WHO HAS A DIRECT OR INDIRECT FINANCIAL INTEREST IN THE TRANSACTION), IT MUST FOLLOW A SPECIFIC PROCEDURE TO MANAGE THE CONFLICT, INCLUDING CONSIDERING ALTERATIVE TRANSACTIONS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. |
| FORM 990, PART VI, SECTION B, LINE 15 | ALL COMPARABILITY DATA DESCRIBED IN THIS STATEMENT INCLUDES DATA ON COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS. COMPENSATION OF CHIEF EXECUTIVE OFFICER (CEO): THE DUTIES OF THE CEO OF ASCO INCLUDE SERVING AS: THE CEO OF ASCO, THE CEO OF ASCO'S NON-PROFIT, 501(C)(3) TAX-EXEMPT RELATED ORGANIZATION, CONQUER CANCER FOUNDATION OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (CC); THE PRESIDENT OF ASCO'S DISREGARDED LIMITED LIABLITY COMPANY, QOPI CERTIFICATION PROGRAM, LLC (QCP); THE PRESIDENT OF ASCO LEASING LLC, AND THE CHAIR OF THE BOARD OF DIRECTORS OF ASCO'S DISREGARDED LIMITED LIABILITY COMPANY, CANCERLINQ LLC (CLQ). ALL ORGANIZATIONS LISTED ARE RELATED ORGANIZATIONS OF ASCO. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE CEO AND ASCO ADDRESSES COMPENSATION OF THE CEO. THE COMPENSATION OF THE CEO WAS DETERMINED BY THE ASCO BOARD OF DIRECTORS, FOLLOWING THE REVIEW AND RECOMMENDATION OF THE BOARD COMPENSATION COMMITTEE. THE COMPENSATION COMMITTEE CONSULTED WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE CEO WAS REASONABLE. THE REVIEW, RECOMMENDATION, AND DETERMINATION OF THE CEO'S COMPENSATION BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2018. SENIOR VICE PRESIDENT & CHIEF LEGAL OFFICER (SVP & CLO): THE COMPENSATION OF THE SVP & CLO WAS DETERMING BY THE ASCO BOARD OF DIRECTORS, FOLLOWING THE REVIEW AND RECOMMENDATION OF THE BOARD COMPENSATION COMMITTEE. THE BOARD COMPENSATION COMMITTEE MADE ITS RECOMMENDATION AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE SVP AND CLO WAS REASONABLE. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE SVP & CLO AND ASCO ADDRESS COMPENSATION OF THE SVP & CLO. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE SVP & CLO BASED ON THE ABOVE DESCRIBED PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2018. VICE PRESIDENT AND CHIEF FINANCIAL OFFICER (VP & CFO): THE COMPENSATION OF THE VP & CFO WAS CONSIDERED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA AND PROVIDED ITS OPINION THAT THE PROPOSED COMPENSATION FOR THE VP & CFO WAS REASONABLE. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE VP & CFO BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2018. SENIOR VICE PRESIDENT & CHIEF MEDICAL OFFICER (SVP & CMO): THE COMPENSATION OF THE SVP & CMO WAS CONSIDERED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE SVP & CMO WAS REASONABLE. THE WRITTEN EMPLOYMENT CONTRACT BETWEEN THE SVP & CMO AND ASCO ADDRESS COMPENSATION OF THE SVP & CMO. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE SVP & CMO BASED ON THE ABOVE DESCRIBED PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2018. EXECUTIVE VICE PRESIDENT & CHIEF PHILANTHROPIC OFFICER (EVP & CPO) OF THE CONQUER CANCER FOUNDATION OF THE AMERICA SOCIETY OF CLINICAL ONCOLOGY (CC): THE EVP & CPO OF CC IS AN EMPLOYEE OF ASCO. THE ASCO BOARD COMPENSATION COMMITTEE CONSIDERED THE COMPENSATION OF THE EVP & CPO OF CC AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA AND PROVIDED ITS OPINION THAT THE COMPENSATION OF THE EXECUTIVE VICE PRESIDENT & CHIEF PHILANTHROPIC OFFICER OF CC WAS REASONABLE. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE EVP & CPO OF CC BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2018. CHIEF EXECUTIVE OFFICER OF CANCERLINQ LLC (CLQ): THE CEO OF CLQ IS AN EMPLOYEE OF ASCO. THE COMPENSATION OF THE CEO OF CLQ WAS CONSIDERED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE ASCO CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA AND PROVIDED ITS OPINION THAT THE COMPENSATION FOR THE CEO OF CLQ WAS REASONABLE. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE SVP & CMO BASED ON THE ABOVE DESCRIBED PROCESS WAS MOST RECENTLY UNDERTAKEN IN 2018. VICE PRESIDENT, INTEGRATED MEDIA AND TECHNOLOGY (VP IMT): THE COMPENSATION OF THE VP IMT WAS CONSIDERED BY THE BOARD COMPENSATION COMMITTEE, AFTER RECEIVING THE RECOMMENDATION OF THE CEO AND CONSULTING WITH INDEPENDENT LEGAL COUNSEL AND ITS INDEPENDENT COMPENSATION CONSULTANT AS FOLLOWS. THE INDEPENDENT COMPENSATION CONSULTANT COLLECTED AND REPORTED ON COMPARABLE MARKET DATA AND PROVIDED ITS OPINION THAT THE COMPENSATION OF THE VICE PRESIDENT, INTEGRATED MEDIA AND TECHNOLOGY WAS REASONABLE. THE CONSIDERATION AND APPROVAL OF THE COMPENSATION OF THE VP IMT BASED ON THE ABOVE DESCRIBED PROCESS WERE MOST RECENTLY UNDERTAKEN IN 2018. |
| FORM 990, PART VI, SECTION C, LINE 19 | ASCO'S GOVERNING DOCUMENTS ARE AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S CERTIFICATE OF INCORPORATION IS ALSO AVAILABLE TO THE PUBLIC THROUGH THE SECRETARY OF STATE OF NEW YORK. ASCO'S CONFLICT OF INTEREST POLICY IS POSTED ON ASCO'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. ASCO'S ANNUAL REPORT IS POSTED ON ASCO'S WEBSITE AND IS AVAILABLE TO THE PUBLIC FROM ASCO UPON REQUEST. |
| FORM 990, PART XI, LINE 9 | GAIN ON INTEREST RATE SWAP $2,587,908 |
| FORM 990 PART IX LINE 11G | DESCRIPTION:COMMISSIONS TOTAL FEES:5488652 |
| FORM 990 PART IX LINE 11G | DESCRIPTION:PUBLIC RELATIONS COORDINATOR TOTAL FEES:1183936 |
| FORM 990 PART IX LINE 11G | DESCRIPTION:OTHER PROFESSIONAL SERVICES TOTAL FEES:21503925 |
| Software ID: | |
| Software Version: |